Daniel Carrizosa, MD, MS, oncologist, Head and Neck Cancer Lung Cancer, Hematology and Medical Oncology (Cancer), Atrium Health Levine Cancer Institute (Thoracic-Pulmonary), discusses the prevalence of 

NRG1 is the primary ligand for the HER3 receptor. When 

 fuses with a partner gene, the fusion can bind and activate HER2 and HER3, leading to downstream signaling and causing tumorigenesis, Carrizosa explains.

Although these rare fusions occur in approximately 0.2% of all solid tumors, at least 10 different solid tumors have been found to harbor them, Carrizosa adds. The 2 most common solid tumors to harbor 

 wild-type pancreatic adenocarcinoma and non–small cell lung cancer, specifically mucinous adenocarcinoma, Carrizosa says.

A large global registry study primarily evaluated patients with lung cancer who harbored 

 fusions, and findings showed that these patients experienced poorer outcomes than those without these fusions, Carrizosa adds. Since these patients do not respond as well to chemotherapy and immunotherapy, there is a need to find a more targeted therapy for the subset of patients whose tumors harbor 

Videos

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.


Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid Tumors

Daniel Carrizosa, MD, MS, oncologist, Head and Neck Cancer Lung Cancer, Hematology and Medical Oncology (Cancer), Atrium Health Levine Cancer Institute (Thoracic-Pulmonary), discusses the efficacy findings from the phase 2 CRESTONE trial (NCT04383210) in patients with 

 fusion–positive, advanced solid tumors.

The phase 2, open-label, international trial evaluated seribantumab in patients with recurrent, locally advanced and/or metastatic solid tumors that harbor 

Data presented during the 2022 Annual ASCO Meeting showed that seribantumab displayed favorable efficacy and safety, Carrizosa says. As of April 2022, the investigator-assessed overall response rate (ORR) achieved with the agent was 33%, with a disease control rate of 92% among 12 evaluable patients, Carrizosa explains. Notably, most patients enrolled to the trial had 

 fusion–positive non–small cell lung cancer, and this subgroup experienced an ORR of 36% with the agent, Carrizosa adds.

Among all patients, there were 2 partial responses and 2 complete responses, showcasing that seribantumab has antitumor activity in patients with 

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.


Daniel Carrizosa, MD, MS

Articles

Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid Tumors

Dr. Carrizosa on the Efficacy Findings of the CRESTONE Trial in NRG1 Fusion–Positive Solid Tumors